Bundle 04 (2024)

Enrollment for this course is now closed, and its accreditation has ended.

Enroll in the current and accredited iteration of the COH/VA course if you would like to earn credit and a certificate of completion.

image

Instruction
2 Learning Modules
image

Time
2.25 Hours
image

Tasks
2 Quizzes

Tumor/Germline Analysis in GCRA Practice, Part 1

Objectives

  • Describe the differences between a high, moderate, and low penetrance cancer susceptibility gene.
  • Counsel a patient about moderate and low penetrance cancer susceptibility genes found on routine clinical testing.
  • Identify that moderate and low penetrance cancer susceptibility genes may not track with the family history of cancer.
  • Recognize that cancer susceptibility genes on clinical panels are not always actionable.

Tumor/Germline Analysis in GCRA Practice, Part 2

Objectives

  • Compare the benefits and challenges of somatic panel, germline panel and paired somatic/germline sequencing.
  • Identify issues related to incidental findings in cancer sequencing.
  • Discriminate strategies used to interpret genomic data.
  • Examine ways that genomic data are changing cancer treatment paradigms.
  • Discuss some of the patient, provider, and system-level challenges to genomic test integration.

Navigating Complex Genetic Test Results - Clonal Hematopoiesis

Objectives

  • Review the various possible mechanisms of both germline and somatic mosaicism.
  • Identify the various mechanisms that can be associated with an altered allelic fraction in a germline genetic test.
  • Discuss approaches to interpreting, further evaluating and following up on genetic test results reporting low allelic fractions.

Padma Sheila Rajagopal, MD, MPH, MSc

Physician-Scientist Early Investigator

Cancer Data Science Laboratory and Women's Malignancies Branch at the National Cancer Institute

Dr. Padma Sheila Rajagopal received her M.D. at Columbia University’s College of Physicians and Surgeons, during which she also received an M.P.H. in quantitative methods with a focus on genetic epidemiology at the Harvard School of Public Health. She completed her internal medicine residency training at the University of Pittsburgh and a fellowship in hematology/oncology with an additional fellowship year focused on cancer genetics at the University of Chicago, where she received an M.Sc. in biomedical informatics. Dr. Rajagopal is a recipient of the Ruth L. Kirschstein F32 Postdoctoral Fellowship and the American Society of Clinical Oncology / Breast Cancer Research Foundation Conquer Cancer Young Investigator Award.

Dr. Rajagopal’s laboratory focuses on how characterizing genomic and transcriptomic interactions between germline variants / inherited cancer syndromes and somatic development in tumors can improve clinical prediction and prognostication in patients with cancer. Her current research focuses on using transcriptomics to characterize breast cancers and treatment responses in patients with hereditary cancer syndromes.

Stacy W. Gray, MD

Deputy Director, Center for Precision Medicine & Professor, Department of Medical Oncology

City of Hope

STACY GRAY, MD, AM, is a Professor and Deputy Director for the Center for Precision Medicine, City of Hope Comprehensive Cancer Center and the Beckman Research Institute. She is also Chief of City of Hope Division Clinical Cancer Genomics, where she leads the clinical, research and educational initiatives of the program.  Dr. Gray's research is focused on realizing the promise of precision cancer medicine for all patients through translational genomics. The Gray lab focuses on improving access to genomic testing and targeted therapies, developing cancer prevention and screening strategies, eliminating care disparities, and rapidly translating innovative and effective new technologies into the clinic through interventions to improve the delivery of precision cancer medicine. Dr. Gray holds multiple leadership roles in a National Institutes of Health research consortium, and has a strong track record of research funding with support from the National Human Genome Research Institute, National Cancer Institute, Agency for Healthcare Research and Quality, American Cancer Society, and American Society of Clinical Oncology.

Components visible upon registration.